Skip to main content
Fig. 10 | Journal of Experimental & Clinical Cancer Research

Fig. 10

From: Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin

Fig. 10

The relationship between Nek2B and LEF-l WRE (a) and LEF-l ORF (b) promoter was analysed using CHIP; (c)Hs578T cells were cotransfected with control or Nek2B-siRNA along with the pGL4-LEF-1-Prom-Luc reporter. Data points represent the mean ± S.D. of triplicate samples from two independent experiments. RLU: Relative Luciferase Units; (d) MDA-MB-231 cells were cotransfected with control or Nek2B along with the pGL4-LEF-1-Prom-Luc reporter; (e)Hs578T cells were cotransfected with control or β-catenin-shRNA along with the pGL4-LEF-1-Prom-Luc reporter; (f)MDA-MB-231 cells were cotransfected with control or β-catenin along with the pGL4-LEF-1-Prom-Luc reporter; (g) MDA-MB-231 cells were transfected with Nek2B alone or Nek2B and β-catenin shRNA together along with the pGL4-LEF-1-prom-Luc reporter. Repression of β-catenin could overcome the promotion of LEF-1 promoter activity by Nek2B; ChIP assays was used to detect the combination of β-catenin and LEF-1 promoter with the silence of Nek2B (h), and detect the binding of Nek2B to the LEF-1 promoter with the silence of β-catenin (i). *P<0.05; **P<0.01

Back to article page